Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis.

OBJECTIVE: To investigate the incidence, clinical features, and treatment of tuberculous pleurisy in AIDS patients. METHODS: We reviewed all cases of pleural tuberculosis in AIDS patients in South Carolina from 1988 through 1994. Clinical findings, test results, treatment, and outcome were analyzed. MAIN RESULTS: Twenty-two (11%) of the 202 AIDS patients with tuberculosis had pleural involvement compared to 6% (169/2,817) pleural involvement in non-AIDS patients (p=0.01). Associated features of AIDS tuberculous pleurisy included substantial weight loss (7.65+/-1.35 kg) and lower lobe infiltrates (12/22; 55%). No difference in pleural fluid characteristics was found when comparing AIDS patients with a serum CD4 count > or =200/microL to patients with CD4 count <200/microL. Two (9%) of the 22 patients died of tuberculosis. Chest radiograph follow-up of 20 patients showed complete resolution in 7, improvement in 10, and no improvement in 3. CONCLUSIONS: In South Carolina, pleural involvement is more common in AIDS patients than in non-AIDS patients with tuberculosis. Tuberculous pleurisy has several atypical features in AIDS patients such as substantial weight loss and lower lobe infiltrates. The outcome of treatment is good for most patients.

Extensive transmission of Mycobacterium tuberculosis among congregated, HIV-infected prison inmates in South Carolina, United States.

BACKGROUND: In August 1999, a prison inmate infected with the human immunodeficiency virus (HIV) was diagnosed with pulmonary tuberculosis (TB). This source patient lived in a prison dormitory housing over 300 HIV-infected men, and was symptomatic for at least 2 months prior to diagnosis. We report a large outbreak of TB in HIV-infected prison inmates with subsequent transmission of Mycobacterium tuberculosis outside the prison. METHODS: Exposed inmates were screened by symptom review, chest radiograph and tuberculin skin test (TST) in September and December 1999. We recorded CD4 cell counts, viral loads and receipt of highly active antiretroviral therapy (HAART). RESULTS: The source patient lived on the right side of a two-sided dormitory exclusively housing HIV-infected men. Of 114 men tested from the right side, 75 (66%) had documented TST conversions. Of 96 converters overall, 82 (85%) had TSTs measuring > or = 15 mm. Within 6 months of diagnosis of TB in the source patient, 30 additional inmates and a healthcare worker who cared for the source patient developed TB disease. Two other inmates developed TB disease in spring of 2001. CONCLUSIONS: We describe extensive transmission of M. tuberculosis in a group of HIV-infected prison inmates with high TST conversion rates and subsequent transmission in the community. In settings where HIV-infected persons are congregated, the consequences of TB outbreaks are magnified.

Compliance with tuberculosis therapy.

The treatment experience in TB control can be a very rewarding time for both the patient and the provider. If the patient is made to feel that the provider cares for him as a person, a meaningful relationship can develop and can have a positive influence on the patient's behavior in taking medications and perhaps even in the direction of his life. Noncompliance with medications unfortunately has been a "given" in the TB control program. The successful program must be patient centered and include the following components: (1) fair and equal treatment of all patients, (2) patient involvement in the plan of care, (3) the most current patient treatment and services, including the availability of DOT for patients with TB infection and disease, and (4) rewards for patients and staff for positive behavior in the completion of treatment. Given current levels of staffing and other resources, some noncompliance will continue even in the best TB programs. Caring and knowledgeable staff members who support the patient-centered approach can make TB treatment a positive experience for both the patient and themselves.

Tuberculosis today in South Carolina: a partnership between DHEC and local physicians.

The DHEC TB Control Division staff in both the central office in Columbia, and in local county health departments are in place to provide the best services for diagnosis, treatment, prevention and control of the disease. Physicians are encouraged to contact either unit to report suspected cases and/or receive consultation. In the future, the partnership to maintain effective tuberculosis control in South Carolina will depend upon the continuing cooperation of local physicians and DHEC.

Correlates of hepatotoxicity and antituberculosis therapy in South Carolina.

This study revealed that 20-30 percent of TB patients who were taking antituberculosis therapy developed elevated liver function tests. Half of the elevation in liver enzyme values occurred within the first two months of treatment. No statistically significant differences between sex, race and liver toxicity was found in this study. The time from initiation of treatment for TB to development of hepatotoxicity was shorter for females and whites. Physicians and public health workers should monitor the liver function tests of TB patients who are taking antituberculosis treatment. Recommendations for monitoring hepatotoxicity vary depending on the age of the patients. For patients less than 35 years old, monthly symptom review for jaundice, acholic stools, fever, anorexia, nausea and vomiting, may be adequate. For older patients, liver function tests are recommended monthly or every one to two months.

Tuberculosis and AIDS in South Carolina: a case-control study.

The epidemiologic features of tuberculosis patients with AIDS or HIV infection in this study do not appear to be different from those reported from previous studies. Tuberculosis patients with AIDS or HIV positive antibody in South Carolina are predominantly black males who live in the urban areas and are 25 to 44 years old. They have more extrapulmonary sites and more anergic reactions to tuberculin tests. Physicians and other public health workers should be aware of the abnormal clinical and laboratory manifestations of tuberculosis patients with AIDS and HIV infection. It is also imperative for tuberculosis control programs to offer counseling and HIV antibody testing to tuberculosis patients.

Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States.

Strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, was responsible for large nosocomial outbreaks in New York in the early 1990s. To describe the spread of strain W outside New York, we reviewed data from epidemiologic investigations, national tuberculosis surveillance, regional DNA fingerprint laboratories, and the Centers for Disease Control and Prevention Mycobacteriology Laboratory to identify potential cases of tuberculosis due to strain W. From January 1992 through February 1997, 23 cases were diagnosed in nine states and Puerto Rico; 8 were exposed to strain W in New York before their diagnosis; 4 of the 23 transmitted disease to 10 others. Eighty-six contacts of the 23 cases are presumed to be infected with strain W; 11 completed alternative preventive therapy. Strain W tuberculosis cases will occur throughout the United States as persons infected in New York move elsewhere. To help track and contain this strain, health departments should notify the Centers for Disease Control and Prevention of cases of tuberculosis resistant to isoniazid, rifampin, streptomycin, and kanamycin.